文献速递毛发、甲与色素性疾病

托法替布治疗斑秃的获益与风险:系统综述与荟萃分析

Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta-analysis.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2019-10-10

该系统综述与荟萃分析纳入14项研究共275例斑秃患者,评估托法替布的安全性与有效性。汇总良好/完全毛发再生率为54.0%(95%CI:46.3%-61.5%),部分应答率为26.1%(20.7-32.2%),约四分之一患者复发,多因停药。不良事件仅轻度,以上呼吸道感染、头痛和痤疮最常见。

要点

  • 托法替布治疗斑秃的汇总良好/完全毛发再生率为54.0%。
  • 部分应答率为26.1%,约四分之一患者复发,多因停药。
  • 不良事件仅轻度,常见上呼吸道感染、头痛和痤疮。

核心结论

  • 托法替布似乎是治疗斑秃有前景的药物,仅伴轻度不良反应。
  • 需要更 thorough 的更大样本随机临床试验进一步评估其安全性和临床疗效。

研究设计与样本

  • 遵循PRISMA指南开展系统综述与荟萃分析,使用ROBINS-I进行质量评估。
  • 纳入14项研究(6项临床试验和8项观察性研究),共275例患者。

主要发现

  • 托法替布在斑秃患者中具有合理有效性。
  • 汇总良好/完全毛发再生率为54.0%(95%CI:46.3%-61.5%)。
  • 汇总部分应答率为26.1%(95%CI:20.7%-32.2%)。
  • 约四分之一患者经历复发,多数报告因停用托法替布所致。
  • 报告的不良反应仅为轻度症状,最常见为上呼吸道感染、头痛和痤疮。

关键数值与推荐

  • 良好/完全毛发再生率54.0%(95%CI:46.3%-61.5%)。
  • 部分应答率26.1%(95%CI:20.7%-32.2%)。

临床怎么用

  • 托法替布可用于斑秃治疗,但需监测复发,尤其是停药后。
  • 常见不良事件为上呼吸道感染、头痛和痤疮,多为轻度。

局限性

  • 需要更 thorough 的更大样本随机临床试验进一步评估安全性和临床疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent insights showed the possibility of using JAK inhibitors for the treatment of alopecia areata (AA). Most of the previous articles evaluated the overall efficacy of existing JAK inhibitors rather than evaluating one of them alone. Currently, the benefit and risk profile of tofacitinib for the treatment of AA is still not clear. OBJECTIVE: To estimate the safety and efficacy of tofacitinib in patients with AA based on summarizing the clinical outcomes. METHODS: The systematic review and meta-analysis was performed according to PRISMA guidelines. ROBINS-I (Risk of Bias in Non-randomized Studies-of Interventions) was used for quality assessment. RESULTS: We enrolled 14 studies including six clinical trials and eight observational studies with 275 patients. The result of meta-analysis showed that tofacitinib has reasonable effectiveness in patients with AA. The pooled good/complete hair regrowth rate of tofacitinib treating patient with AA was 54.0% (95% CI: 46.3%-61.5%), and the pooled rate of partial response in patients with AA taking tofacitinib was 26.1% (20.7-32.2%). Approximately a quarter of patients had experience of relapse, most of which was reported due to discontinuation of tofacitinib. In terms of toxicity, reported adverse effects included only mild symptoms. Upper respiratory infection, headache and acne were the most common adverse events. CONCLUSION: Tofacitinib seems to be a promising drug for the treatment of AA with only mild adverse effects. More thorough larger sized randomized clinical trials are required to further assess the safety and clinical efficacy of tofacitinib for the treatment of AA.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Guo L, Feng S, Sun B, et al. Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta-analysis. J Eur Acad Dermatol Venereol. 2019. PMID: 31494993. doi:10.1111/jdv.15937

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。